We conducted a randomized , double-blind , placebo-controlled , dose-ranging , phase 2 study to evaluate ISIS 304801 in untreated patients with fasting triglyceride levels between 350 mg per deciliter ( 4.0 mmol per liter ) and 2000 mg per deciliter ( 22.6 mmol per liter ) ( ISIS 304801 monotherapy cohort ) , as well as in patients receiving stable fibrate therapy who had fasting triglyceride levels between 225 mg per deciliter ( 2.5 mmol per liter ) and 2000 mg per deciliter ( ISIS 304801-fibrate cohort ) .